Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
[HTML][HTML] Current therapy and drug resistance in metastatic castration-resistant prostate cancer
M Cai, XL Song, XA Li, M Chen, J Guo, DH Yang… - Drug Resistance …, 2023 - Elsevier
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …
A systematic review of artificial intelligence techniques in cancer prediction and diagnosis
Artificial intelligence has aided in the advancement of healthcare research. The availability
of open-source healthcare statistics has prompted researchers to create applications that aid …
of open-source healthcare statistics has prompted researchers to create applications that aid …
The DNA methylation landscape of advanced prostate cancer
Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …
methylation landscape of metastatic cancer has never been defined. Through whole …
[HTML][HTML] Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment
Bone metastases are devastating complications of cancer. They are particularly common in
prostate cancer (PCa), represent incurable disease, and are refractory to immunotherapy …
prostate cancer (PCa), represent incurable disease, and are refractory to immunotherapy …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
Treatment of advanced prostate cancer
MY Teo, DE Rathkopf, P Kantoff - Annual review of medicine, 2019 - annualreviews.org
The therapeutic landscape of prostate cancer has been transformed over the last decade by
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …
Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology
JL Mohler, ES Antonarakis, AJ Armstrong… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …
risk stratification and workup, treatment options for localized disease, and management of …